methyl[1-(1-methyl-1H-pyrazol-4-yl)ethyl]amine | 1007459-61-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: methyl[1-(1-methyl-1H-pyrazol-4-yl)ethyl]amine
• 英文别名: N-methyl-1-(1-methylpyrazol-4-yl)ethanamine
• CAS: 1007459-61-1
• 化学式: C₇H₁₃N₃
• mdl: MFCD08700773
• 分子量: 139.2
• InChiKey: KFDNTYSILYMRBA-UHFFFAOYSA-N

物化性质

• 沸点：
  207.6±15.0 °C(Predicted)
• 密度：
  1.03±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.571
• 拓扑面积：
  29.8
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
  申请人：Fuchs Klaus

  公开号：US20090042867A1

  公开（公告）日：2009-02-12

  The invention relates to substituted 1,2-ethylenediamines of general formula (I), wherein the radicals R 1 to R 13 , A, B, L, and i are defined as indicated in the description and the claims, as well as the use thereof for treating Alzheimer's disease (AD) and similar diseases.

  该发明涉及通式（I）的取代1,2-乙二胺化合物，其中基团R1至R13，A，B，L和i的定义如描述和索赔中所示，以及其用于治疗阿尔茨海默病（AD）和类似疾病的用途。
• AZETIDINE POLYSUBSTITUTED COMPOUNDS, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF
  申请人：Bernardelli Patrick

  公开号：US20110152236A1

  公开（公告）日：2011-06-23

  The invention relates to compounds of the formula (I) where: R is a (C 1 -C 6 )alkyl group, a halo(C 1 -C 6 )alkyl group; R1 is a hydrogen atom; R2 is a heteroaromatic group or a heteroaromatic(C 1 -C 4 )alkyl group, said groups being optionally substituted; R3 and R4 represent independently from each other an optionally substituted phenyl group; Y is a hydrogen atom, a halogen, a cyano, a (C 1 -C 6 )alkyl group, a halo(C 1 -C 6 )alkyl group, a (C 1 -C 6 )alkoxy group, a halo(C 1 -C 6 )alkoxy group or a (C 1 -C 6 )alkylS(O) p group; and p is 0 to 2. Said compounds can be in the form — of a base or a salt for addition to an acid. The invention also relates to a method for preparing same and to the therapeutic application thereof.

  该发明涉及化合物的结构式（I），其中：R是（C1-C6）烷基基团，卤代（C1-C6）烷基基团；R1是氢原子；R2是杂环芳基团或杂环芳基（C1-C4）烷基基团，这些基团可以选择性地被取代；R3和R4分别独立地表示一个可以选择性取代的苯基团；Y是氢原子、卤素、氰基、（C1-C6）烷基基团、卤代（C1-C6）烷基基团、（C1-C6）烷氧基、卤代（C1-C6）烷氧基或（C1-C6）烷基S（O）p基团；p为0至2。所述化合物可以以盐的形式存在，用于与酸发生加成反应。该发明还涉及制备该化合物的方法及其治疗应用。
• Substituted 1,2-ethylenediamines, Methods for Preparing Them and Uses Thereof
  申请人：Eickmeier Christian

  公开号：US20090325940A1

  公开（公告）日：2009-12-31

  The present invention relates to substituted 1,2-ethylenediamines of general formula (I) wherein the groups R 1 to R 15 , A, B, L, i as well as X 1 -X 4 are defined as in the specification and claims and the use thereof for the treatment of Alzheimer's disease (AD) and similar diseases.
• US7713961B2
  申请人：——

  公开号：US7713961B2

  公开（公告）日：2010-05-11
• [DE] VERBINDUNGEN ZUR BEHANDLUNG DER ALZHEIMER ERKRANKUNG<br/>[EN] COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE<br/>[FR] COMPOSES POUR LE TRAITEMENT DE LA MALADIE D'ALZHEIMER
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2007017509A1

  公开（公告）日：2007-02-15

  [EN] The invention relates to substituted 1,2-ethylenediamines of general formula (I), wherein the radicals R¹ to R¹³, A, B, L, and i are defined as indicated in the description and the claims, as well as the use thereof for treating Alzheimer's disease (AD) and similar diseases.
  [FR] La présente invention concerne des 1,2-éthylènediamines de formule générale (I) dans laquelle les radicaux R¹ à R¹³, A, B, L et i sont tels que définis dans la description et les revendications, et l'utilisation desdites substances pour traiter la maladie d'Alzheimer (AD) et des pathologies similaires.
  [DE] Gegenstand der vorliegenden Erfindung sind substituierte 1,2-Ethylendiamine der allgemeinen Formel (I) wobei die Reste R¹ bis R¹³, A, B, L und i wie in der Beschreibung und den Ansprüchen definiert sind und deren Verwendung zur Behandlung der Alzheimer Erkrankung (AD) und ähnlicher Erkrankungen.